By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Esperion Therapeutics, Inc. 

3621 S. State Street
695 KMS Place
Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-332-0506 Fax: 734-332-0516


SEARCH JOBS
Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including atherosclerosis, as they relate to high density lipoprotein cholesterol, "HDL-C", also known as the "good" cholesterol.

The technology platform for Esperion is based upon the Reverse Lipid Transport (RLT) pathway. The RLT pathway is responsible for removing excess cholesterol and other lipids from arterial walls and other tissues for transport to the liver and elimination from the body. The Company's product candidates work by stimulating the RLT pathway through the enhancement of key HDL properties, which may result in improved vascular structure and function. Esperion is focusing its efforts on developing both acute and chronic therapies for cardiovascular and metabolic diseases.

Esperion was founded in 1998 by, among others, members of the Warner-Lambert/Parke-Davis (now Pfizer) team that discovered and developed atorvastatin, the highly successful multibillion-dollar drug. Since that time, an additional group of exceptional scientists and specialists has joined the Company. Many of these individuals have been instrumental in the discovery, development and commercialization of several of the pharmaceutical industry's most successful therapies. It is this combined team that makes Esperion a leading enterprise in HDL drug discovery and research.

Key Management:

  • Roger Newton, Ph.D.
    President and CEO
  • Timothy Mayleben
    Chief Operating Officer and CFO

    Last Updated: 01-18-05

    Key Statistics


    Email: info@esperion.com
    Ownership: Public

    Web Site: Esperion
    Employees:
    Symbol: ESPR
     



  • Industry
    Biotechnology






    Company News
    Esperion (ESPR) Announces Publication Of Definitive Paper On Bempedoic Acid Mechanism Of Action In Nature Communications 11/29/2016 10:16:15 AM
    Esperion (ESPR) To Present At The Stifel 2016 Healthcare Conference 11/10/2016 2:08:45 PM
    Esperion (ESPR) Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results 11/4/2016 9:12:55 AM
    Esperion (ESPR) To Present At The Credit Suisse 25th Annual Healthcare Conference 11/2/2016 9:09:36 AM
    Esperion (ESPR) Release: Bempedoic Acid Global Phase 3 Clinical Program To Include Patients On Any Statin At Any Dose 10/13/2016 11:26:14 AM
    Esperion (ESPR) Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results 8/5/2016 9:35:03 AM
    Esperion (ESPR) Falls on Lack of FDA Clarity for Cholesterol Drug 6/29/2016 8:06:10 AM
    Esperion (ESPR) Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results 5/4/2016 10:09:56 AM
    Esperion (ESPR) To Present At The Barclays Global Healthcare Conference 3/9/2016 8:13:44 AM
    Esperion (ESPR) Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter And Full Year 2015 Financial Results 2/26/2016 9:06:48 AM
    12345678910...
    //-->